TABLE 18Summary of relapse/recurrence in patients taking TAM in relation to CYP2D6 status: Asian patients genotyped for the *10 allele

Cohort/studyAlleles testedOutcome definitionSummary of findings
Kiyotani et al. cohort:114

Kiyotani et al. 200888
*4, *5, *6, *10, *14, *18, *21, *41RFS: the period between surgical treatment to the recurrence of a breast cancer (i.e. local or distant recurrence or contralateral breast cancer)Cox HR (unadjusted), RFS:

*10/*10 vs wt/*10: HR 2.19; 95% CI 0.24 to 19.79; p = 0.49

*10/*10 vs wt/wt: HR 8.67; 95% CI 1.06 to 71.09; p = 0.036

Cox HR (adjusted for tumour size), RFS:

*10/*10 vs wt/wt: HR 10.04; 95% CI 1.17 to 86.27; p = 0.044
Kiyotani et al. 2010114In Kiyotani et al. 2010114 also genotyped for *36Cox HR (adjusted for tumour size and nodal status), RFS:

wt/*10 vs wt/wt: HR 4.44; 95% CI 1.31 to 15.00

*10/*10 vs wt/wt: HR 9.52; 95% CI 2.79 to 32.45; p < 0.001
Xu et al. 2008101*10DFS: time from date of diagnosis to first distant metastasis or death from breast cancer without a recorded relapseCox HR (adjusted for age, clinical stage, LN status, tumour size, adjuvant therapy, surgery, C-erbB2 status, and ER or PgR):

TAM: *10/*10 vs wt/wt + wt/*10: HR 4.7; 95% CI 1.1 to 20.0; p = 0.04

No TAM: CYP2D6 *10 genotype was not significantly associated with DFS (p = 0.99)
Okishiro et al. 200993*10RFS: distant recurrences, locoregional recurrences, ipsilateral in-breast recurrences, and contralateral breast cancers were includedCox HR (unadjusted):

*10/*10 vs. wt/wt + wt/*10: HR 0.94; 95% CI 0.34 to 2.60; p = 0.95

Cox HR (adjusted for tumour size, LN status, histological grade, PgR status, HER2 status and adjuvant therapy)

*10/*10 vs. wt/wt + wt/*10: HR 0.6; 95% CI 0.18 to 1.92; p = 0.39
Toyama et al. 200997*10DFS: time from the date of primary surgery to the first locoregional recurrence, distant metastasis, ipsilateral breast recurrence or contralateral breast cancersIt is stated that no associations were found between the *10 genotype and DFS. No HRs have yet been calculated (Tatsuya Toyama, personal communication)

From: 3, Assessment of clinical effectiveness

Cover of The Clinical Effectiveness and Cost-Effectiveness of Genotyping for CYP2D6 for the Management of Women with Breast Cancer Treated with Tamoxifen: A Systematic Review
The Clinical Effectiveness and Cost-Effectiveness of Genotyping for CYP2D6 for the Management of Women with Breast Cancer Treated with Tamoxifen: A Systematic Review.
Health Technology Assessment, No. 15.33.
Fleeman N, Saborido CM, Payne K, et al.
Southampton (UK): NIHR Journals Library; 2011 Sep.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.